SPARC has been used as a biomarker for both diagnosis and prognosis (38) and functions as a sensitizer to chemotherapy by enhancing apoptosis with interfering activity of Bcl-2 (39) in colon cancer. This evidence concerns the gene BCL2 and colonic neoplasm.